AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22093057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19799810 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction-concurrent chemoradiotherapy (IC/CCRT)
Number of subjects: 400
Study 19799810 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy and radiotherapy (IC/RT)
Number of subjects: 400
Study 17613561 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intensity of ultrasound
Number of subjects: 44
Study 17613561 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity application of ultrasound
Number of subjects: 44
Study 15716206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical hyaluronic acid therapy (40 mg weekly for 10 weeks)
Number of subjects: 48
Study 15716206 — intervention group
Group type: COMPARATOR
Intervention: Control group (C(max) <350 cc)
Number of subjects: 48
Study 15716206 — intervention group
Group type: COMPARATOR
Intervention: Control group (C(max) >/=350 cc)
Number of subjects: 48
Study 12036188 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas' disease group
Number of subjects: 36
Study 12036188 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 10076773 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10,000 epinephrine hydrochloride
Number of subjects: 26
Study 10076773 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 26
Study 8719069 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP chemotherapy (vindesine 3 mg/m2 days 1 and 8, ifosfamide 1200 mg/m2, cisplatin 30 mg/m2 days 1, 2 and 3, repeated every 4 weeks, up to six cycles)
Number of subjects: 64
Study 2024842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (28% oxygen by Venturi face mask)
Number of subjects: 22
Study 2024842 — intervention group
Group type: COMPARATOR
Intervention: Air (by Venturi face mask)
Number of subjects: 22
Study 7004808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose (50 g twice a day)
Number of subjects: 10
Study 7004808 — intervention group
Group type: COMPARATOR
Intervention: Neomycin (3 g/day) plus milk of magnesia
Number of subjects: 10
Study 31549334 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (M)
Number of subjects: 40
Study 31549334 — intervention group
Group type: COMPARATOR
Intervention: Saccharomyces boulardii (SB)
Number of subjects: 40
Study 31549334 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole + Saccharomyces boulardii (M + SB)
Number of subjects: 40
Study 31610249 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pelvis radiotherapy (WPRT) 46Gy in 23 fractions + 15Gy single dose HDR BT
Number of subjects: 812
Study 31610249 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only radiotherapy (PORT) 37.5Gy in 15 fractions + 15Gy single dose HDR BT
Number of subjects: 812
Study 31610249 — intervention group
Group type: EXPERIMENTAL
Intervention: WPRT
Number of subjects: 812
Study 31610249 — intervention group
Group type: COMPARATOR
Intervention: PORT
Number of subjects: 812
Study 31610249 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WPRT and PORT
Number of subjects: 812
Study 27911263 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS group (n=45)
Number of subjects: 90
Study 27911263 — intervention group
Group type: COMPARATOR
Intervention: US group (n=45)
Number of subjects: 90
Study 26427109 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 81
Study 26427109 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion (Mox)
Number of subjects: 81
Study 23801770 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg neostigmine
Number of subjects: 21
Study 23801770 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous butylscopolamine
Number of subjects: 21
Study 23801770 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 21
Study 21108675 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and education via telephone one week after surgery and face-to-face support six months after surgery
Number of subjects: 164
Study 21108675 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 164
Study 19799101 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK+ (walking program supplemented by tasks designed to challenge balance and mobility)
Number of subjects: 31
Study 19799101 — intervention group
Group type: COMPARATOR
Intervention: WALK (traditional walking program)
Number of subjects: 31
Study 17513410 — intervention group
Group type: EXPERIMENTAL
Intervention: P125 (1.00 g protein . kg BW(‐1). d(‐1))
Number of subjects: 22
Study 17513410 — intervention group
Group type: EXPERIMENTAL
Intervention: P94 (0.75 g protein . kg BW(‐1). d(‐1))
Number of subjects: 22
Study 17513410 — intervention group
Group type: EXPERIMENTAL
Intervention: P63 (0.50 g protein . kg BW(‐1). d(‐1))
Number of subjects: 22
Study 17513410 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 22
Study 15155598 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-comic intervention
Number of subjects: 658
Study 15155598 — intervention group
Group type: COMPARATOR
Intervention: Placebo comic (Control)
Number of subjects: 658
Study 15155598 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-drama (among those who recalled it)
Number of subjects: 658
Study 15155598 — intervention group
Group type: EXPERIMENTAL
Intervention: No recall of radio-drama (among those who did not recall it)
Number of subjects: 658
Study 11989524 — intervention group
Group type: EXPERIMENTAL
Intervention: Herceptin® (various regimens and durations)
Number of subjects: 12000
Study 11989524 — intervention group
Group type: EXPERIMENTAL
Intervention: Herceptin® (adjuvant therapy)
Number of subjects: 12000
Study 10518855 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial dentifrice containing 0.45% stannous fluoride
Number of subjects: 384
Study 10518855 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitartar dentifrice containing 0.243% sodium fluoride and 5% pyrophosphate
Number of subjects: 384
Study 10518855 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial dentifrice containing 0.24% sodium fluoride and 0.30% triclosan/copolymer
Number of subjects: 384
Study 10518855 — intervention group
Group type: COMPARATOR
Intervention: Bottled distilled water (negative control)
Number of subjects: 384
Study 7521542 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 68
Study 7521542 — intervention group
Group type: COMPARATOR
Intervention: Parenteral feeding
Number of subjects: 68
Study 2757898 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (SA)
Number of subjects: 0
Study 2757898 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (FLU)
Number of subjects: 0
Study 326303 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 4% eye drops (Tenormin)
Number of subjects: 8
Study 326303 — intervention group
Group type: COMPARATOR
Intervention: Saline 0-9% (control)
Number of subjects: 8
Study 31250180 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model (clinical + radiomic features)
Number of subjects: 198
Study 31250180 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with only clinical features
Number of subjects: 198
Study 31250180 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with only radiomic features
Number of subjects: 198
Study 27993911 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oxytocin infusion (10 U in 500 mL normal saline at 36 mL/hour for 4 hours)
Number of subjects: 59
Study 27993911 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oxytocin infusion plus an additional 2 U of oxytocin given over 10 min immediately after birth
Number of subjects: 59
Study 25951636 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Western medical treatment plus Compound Yindan Decoction (CYD)
Number of subjects: 60
Study 25951636 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Western medical treatment alone
Number of subjects: 60
Study 24082369 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized temporary biventricular pacing
Number of subjects: 5
Study 24082369 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm
Number of subjects: 5
Study 24082369 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing at matched heart rate
Number of subjects: 5
Study 21896874 — intervention group
Group type: EXPERIMENTAL
Intervention: Small particle size CaCO(3) (13.5 μm)
Number of subjects: 31
Study 21896874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21896874 — intervention group
Group type: EXPERIMENTAL
Intervention: Large particle size CaCO(3) (18 μm)
Number of subjects: 31
Study 20210231 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (150 mg orally twice daily on days 2 through 5)
Number of subjects: 52
Study 17349809 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-PRP approximately T (group A)
Number of subjects: 0
Study 17349809 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV plus PRP approximately T at separate injection sites (group B)
Number of subjects: 0
Study 12765853 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC‐687 (5 mg)
Number of subjects: 20
Study 12765853 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC‐687 (10 mg)
Number of subjects: 20
Study 12765853 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC‐687 (15 mg)
Number of subjects: 20
Study 12765853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10912743 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 142
Study 10912743 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 142
Study 9313756 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 9
Study 9313756 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 9
Study 8453848 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg three times a day for 1 week
Number of subjects: 12
Study 8453848 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.05 mg/kg) intravenously
Number of subjects: 12
Study 3544186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg)
Number of subjects: 20
Study 3544186 — intervention group
Group type: COMPARATOR
Intervention: Atropine (1 mg)
Number of subjects: 20
Study 31904028 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical endoscopic sinus surgery (RESS)
Number of subjects: 81
Study 31904028 — intervention group
Group type: EXPERIMENTAL
Intervention: RESS+Draf 3 surgery
Number of subjects: 81
Study 31904028 — intervention group
Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 81
Study 31904028 — intervention group
Group type: EXPERIMENTAL
Intervention: RESS
Number of subjects: 81
Study 31904028 — intervention group
Group type: EXPERIMENTAL
Intervention: RESS+Draf 3
Number of subjects: 81
Study 30209073 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block administered by paramedics as early prehospital pain relief.
Number of subjects: 71
Study 30209073 — intervention group
Group type: EXPERIMENTAL
Intervention: Scratchcards for random allocation concealment.
Number of subjects: 71
Study 30209073 — intervention group
Group type: EXPERIMENTAL
Intervention: Scratchcards as a method of random allocation.
Number of subjects: 71
Study 26739688 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda (180 μg weekly for 48 weeks)
Number of subjects: 163
Study 26739688 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (weekly for 48 weeks)
Number of subjects: 163
Study 24996857 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary advancement (n=51)
Number of subjects: 191
Study 24996857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimaxillary procedure (n=102)
Number of subjects: 191
Study 24996857 — intervention group
Group type: COMPARATOR
Intervention: Mandibular setback (n=38)
Number of subjects: 191
Study 24996857 — intervention group
Group type: EXPERIMENTAL
Intervention: All surgical approaches
Number of subjects: 191
Study 22622860 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 118
Study 22622860 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 118
Study 22622860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 20691418 — intervention group
Group type: EXPERIMENTAL
Intervention: Green laser (532‐nm wavelength)
Number of subjects: 30
Study 20691418 — intervention group
Group type: COMPARATOR
Intervention: Infrared laser (810‐nm wavelength)
Number of subjects: 30
Study 19014023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with distilled water
Number of subjects: 36
Study 19014023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with 17% EDTAC
Number of subjects: 36
Study 19014023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with 1% sodium hypochlorite
Number of subjects: 36
Study 19014023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with 2% chlorhexidine
Number of subjects: 36
Study 12661258 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-saving operations
Number of subjects: 0
Study 9875193 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulfate
Number of subjects: 6
Study 9875193 — intervention group
Group type: COMPARATOR
Intervention: General use of zinc sulfate
Number of subjects: 6
Study 7913205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion (2.4 mU/kg/min for 2 minutes followed by 10 minutes off)
Number of subjects: 6
Study 7913205 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin infusion (0.4 mU/kg/min)
Number of subjects: 6
Study 7913205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion
Number of subjects: 6
Study 7913205 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin infusion
Number of subjects: 6
Study 2575014 — intervention group
Group type: EXPERIMENTAL
Intervention: CV 205-502 (CV)
Number of subjects: 6
Study 2575014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30399036 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed TB (MLR 0.407, IQR 0.378-0.675)
Number of subjects: 160
Study 30399036 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR cutoff value of 0.378
Number of subjects: 160
Study 30399036 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-TB treatment MLR
Number of subjects: 160
Study 28673251 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced linkage to HIV care intervention
Number of subjects: 600
Study 28673251 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (paper-based referrals)
Number of subjects: 600
Study 25659828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive zonisamide (target dose 8 mg/kg/day; maximum 500 mg/day)
Number of subjects: 179
Study 25659828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive zonisamide
Number of subjects: 179
Study 23571365 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced daily cleaning of ICU room surfaces
Number of subjects: 132
Study 23571365 — intervention group
Group type: COMPARATOR
Intervention: Routine care in control rooms
Number of subjects: 132
Study 21983354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal(®) 0.25 mL
Number of subjects: 360
Study 21983354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epaxal(®) 0.5 mL
Number of subjects: 360
Study 21983354 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix(®) Junior
Number of subjects: 360
Study 21983354 — intervention group
Group type: COMPARATOR
Intervention: All vaccines
Number of subjects: 360
Study 21983354 — intervention group
Group type: COMPARATOR
Intervention: All study vaccines
Number of subjects: 360
Study 19233181 — intervention group
Group type: COMPARATOR
Intervention: Low-dose celecoxib (200 mg twice daily)
Number of subjects: 1660
Study 19233181 — intervention group
Group type: COMPARATOR
Intervention: High-dose celecoxib (400 mg twice daily)
Number of subjects: 1660
Study 19233181 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (both doses)
Number of subjects: 1660
Study 16309928 — intervention group
Group type: EXPERIMENTAL
Intervention: MSM 3g twice a day for 12 weeks (6g/day total)
Number of subjects: 50
Study 16309928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15639691 — intervention group
Group type: EXPERIMENTAL
Intervention: multidose dry powder inhaler (mDPI)
Number of subjects: 80
Study 15639691 — intervention group
Group type: COMPARATOR
Intervention: capsule dry powder inhaler (cDPI)
Number of subjects: 80
Study 11411192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 51
Study 9421103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 480 mg daily (Group-1)
Number of subjects: 20
Study 9421103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tamoxifen, Group-2)
Number of subjects: 20
Study 8273245 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid lotion with additives
Number of subjects: 60
Study 8273245 — intervention group
Group type: COMPARATOR
Intervention: Plain steroid lotion
Number of subjects: 60
Study 3432562 — intervention group
Group type: EXPERIMENTAL
Intervention: BN 52063
Number of subjects: 8
Study 3432562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31253613 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine system (DMS) comprising an oral sensor tablet coencapsulated with an antipsychotic (aripiprazole, olanzapine, quetiapine, or risperidone), non-medicated wearable patch, mobile application, and web-based dashboard.
Number of subjects: 0
Study 28087928 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of weekly directly observed therapy
Number of subjects: 7061
Study 28087928 — intervention group
Group type: COMPARATOR
Intervention: 9 months of daily self-administered therapy
Number of subjects: 7061
Study 24968251 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) with 5 or 10 mg transdermal T patch daily for 12 months
Number of subjects: 13
Study 24308044 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity group
Number of subjects: 0
Study 24308044 — intervention group
Group type: COMPARATOR
Intervention: Lower physical activity group
Number of subjects: 0
Study 22075320 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system (RAS) inhibitors
Number of subjects: 25
Study 22075320 — intervention group
Group type: COMPARATOR
Intervention: Historical untreated controls
Number of subjects: 25
Study 19635169 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral heme iron polypeptide (HIP; Proferrin ES) - 1 tablet twice daily
Number of subjects: 0
Study 19635169 — intervention group
Group type: COMPARATOR
Intervention: Slow-release ferrous sulphate - 1 tablet twice daily (control)
Number of subjects: 0
Study 19635169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (HIP and control)
Number of subjects: 0
Study 16684267 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of methanolic extract of L. pacari (n = 55)
Number of subjects: 100
Study 16684267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 45)
Number of subjects: 100
Study 15087552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise therapy with immobilization of the unimpaired arm (forced use)
Number of subjects: 56
Study 15087552 — intervention group
Group type: COMPARATOR
Intervention: Intensive exercise therapy without immobilization of the unimpaired arm (forced use)
Number of subjects: 56
Study 11334904 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute 72-hour fast (7 women in each group)
Number of subjects: 22
Study 11334904 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 women in each group, not fasting)
Number of subjects: 22
Study 9235493 — intervention group
Group type: COMPARATOR
Intervention: 2.4 million units of penicillin G benzathine
Number of subjects: 541
Study 9235493 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced therapy with 2.4 million units of penicillin G benzathine plus a 10-day course of amoxicillin and probenecid
Number of subjects: 541
Study 8496858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg/day)
Number of subjects: 142
Study 8496858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 3099588 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 54
Study 3099588 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 54
Study 31628465 — intervention group
Group type: EXPERIMENTAL
Intervention: PYY (0.4 pmol/kg/min)
Number of subjects: 18
Study 30022357 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management Program (IY TCM)
Number of subjects: 1817
Study 27529374 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiming device used during operation (Experimental group)
Number of subjects: 64
Study 27529374 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aiming device)
Number of subjects: 64
Study 24731365 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oligosaccharides (SBOS) combined with insulin treatment
Number of subjects: 97
Study 24731365 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 97
Study 23250527 — intervention group
Group type: EXPERIMENTAL
Intervention: Imudon therapy in combination with traditional methods
Number of subjects: 320
Study 23250527 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 320
Study 20461807 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 0.5 mg
Number of subjects: 263
Study 20461807 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 1 mg
Number of subjects: 263
Study 20461807 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 2 mg
Number of subjects: 263
Study 20461807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 20461807 — intervention group
Group type: EXPERIMENTAL
Intervention: All perampanel groups
Number of subjects: 263
Study 20461807 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 263